

CLAIMS

What is claimed is:

1. A method for the treatment or prophylaxis of a PDE IV- or a TNF-alpha-related condition in a mammal in need of such treatment or prophylaxis comprising administering to the mammal an amount of a PDE IV inhibitor and an amount of a TNF-alpha antagonist wherein the amount of the PDE IV inhibitor and the amount of the TNF-alpha antagonist together comprise a therapy effective for the treatment or prophylaxis of a PDE IV- or a TNF-alpha-related condition.
2. The method of Claim 1, wherein the TNF-alpha antagonist is selected from the group consisting of a metalloproteinase inhibitor, a tetracycline TNF-alpha antagonist, a fluoroquinolone TNF-alpha antagonist, and a quinolone TNF-alpha antagonist.
3. The method of Claim 1, wherein the PDE IV inhibitor is selected from the group consisting of roflumilast, cilomilast, ZK-117137, bamifylline, dyphylline, ibudilast, and theophylline.
4. The method of Claim 1, wherein the PDE IV inhibitor is selected from the group consisting of a quinazolinedione PDE IV inhibitor, a xanthine PDE IV inhibitor, and a benzamide PDE IV inhibitor.
5. The method of Claim 4, wherein the PDE IV inhibitor is selected from the group consisting of 1-cyclopentyl-N-(3,5-dichloropyridin-4-yl)-3-ethyl-1H-indazole-6-carboxamide, 1-cyclopentyl-3-ethyl-6-(2-methylphenyl)-1,3a,4,5,6,7a-hexahydro-7H-pyrazolo[3,4-c]pyridin-7-one, N-(4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indol-3-yl)-1H-indole-2-carboxamide, CI-1118, 4-[4-cyclopropyl-6-(cyclopropylamino)-1,3,5-triazin-2-yl]-1lambda~4~,4-thiazinane-1,1-diol, and N-cyclopropyl-4-(2-methylcyclopropyl)-6-(2-methylmorpholin-4-yl)-1,3,5-triazin-2-amine, atizoram, filaminast, piclamilast, tibenelast, CDP 840, GW 3600, NCS 613, PDB 093, Ro 20-1724, RS 25344-000, SKF 107806, XT-44, tolafentrine, zardaverine, T-2585, SDZ-ISQ-844, SB 207499, RPR-117658A, L-787258, E-4021, GF-248, IPL-4088, CP-353164, CP-146523, CP-293321, T-611, WAY-126120, WAY-

122331, WAY-127093B, PDB-093, CDC-801, CC-7085, CDC-998, CH-3697, CH-3442, CH-2874, CH-4139, RPR-114597, RPR-122818, KF-19514, CH-422, CH-673, CH-928, KW-4490, Org 20241, Org 30029, VMX 554, VMX 565, benafentrine, trequinsin, EMD 54622, RS 17597, Nitraquazone, oxagrelate, T-440.

6. The method of Claim 2, wherein the TNF-alpha antagonist is a TNF-alpha antibody.
7. The method of Claim 6, wherein the TNF-alpha antibody is selected from the group consisting of infliximab, etanercept, CytoFAb, AGT-1, afelimomab, PassTNF, and CDP-870.
8. The method of Claim 2, wherein the TNF-alpha antagonist is selected from the group consisting of thalidomide, Onercept, Pegsunercept, interferon-gamma, interleukin-1, pentoxifylline, pimobeddan, lactoferrin, melatonin, nitrogen oxide, naphthopyridine, a lazaroid, hydrazine sulfate, ketotifen, tenidap, a cyclosporin, peptide T, sulfasalazine, thorazine, an antioxidant, a cannabinoid, glycyrrhizin, sho-saiko-to, and L-carnitine.
9. A therapeutic composition comprising an amount of a PDE IV inhibitor and an amount of a TNF-alpha antagonist and a pharmaceutically acceptable excipient.
10. The therapeutic composition of Claim 9, wherein the PDE IV inhibitor is selected from the group consisting of roflumilast, cilomilast, ZK-117137, bamifylline, dyphylline, ibudilast, and theophylline.
11. The therapeutic composition of Claim 9, wherein the PDE IV inhibitor is selected from the group consisting of a catechol ether PDE IV inhibitor, a quinazolinedione PDE IV inhibitor, a xanthine PDE IV inhibitor, and a benzamide PDE IV inhibitor.
12. The therapeutic composition of Claim 11, wherein the PDE IV inhibitor is selected from the group consisting of 1-cyclopentyl-N-(3,5-dichloropyridin-4-yl)-3-ethyl-1H-indazole-6-carboxamide, 1-cyclopentyl-3-ethyl-6-(2-methylphenyl)-1,3a,4,5,6,7a-hexahydro-7H-pyrazolo[3,4-c]pyridin-7-one, N-(4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indol-3-yl)-1H-indole-2-carboxamide, CI-1118, 4-[4-cyclopropyl-6-(cyclopropylamino)-1,3,5-triazin-2-yl]-1-lambda~4~,4-thiazinane-1,1-diol, and N-cyclopropyl-4-(2-

methylcyclopropyl)-6-(2-methylmorpholin-4-yl)-1,3,5-triazin-2-amine, atizoram, filaminast, piclamilast, tibenelast, CDP 840, GW 3600, NCS 613, PDB 093, Ro 20-1724, RS 25344-000, SKF 107806, XT-44, tolafentrine, zardaverine, T-2585, SDZ-ISQ-844, SB 207499, RPR-117658A, L-787258, E-4021, GF-248, IPL-4088, CP-353164, CP-146523, CP-293321, T-611, WAY-126120, WAY-122331, WAY-127093B, PDB-093, CDC-801, CC-7085, CDC-998, CH-3697, CH-3442, CH-2874, CH-4139, RPR-114597, RPR-122818, KF-19514, CH-422, CH-673, CH-928, KW-4490, Org 20241, Org 30029, VMX 554, VMX 565, benafentrine, trequinsin, EMD 54622, RS 17597, Nitraquazone, oxagrelate, T-440.

13. The therapeutic composition of Claim 9, wherein the TNF-alpha antagonist is a TNF-alpha antibody.
14. The therapeutic composition of Claim 13, wherein the TNF-alpha antibody is selected from the group consisting of infliximab, etanercept, CytoFAb, AGT-1, afelimomab, PassTNF, and CDP-870.
15. A kit for the purpose of treatment or prophylaxis of a PDE IV- or a TNF-alpha-related condition in a mammal in need of such treatment or prophylaxis, the kit comprising a dosage form comprising a PDE IV inhibitor and a dosage form comprising a TNF-alpha antagonist.